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Debating whether the end 
of AIDS is ‘a reality or 
myth’ (given the 33% global 
reduction in deaths over the 
past decade, and the hugely 
successful up-scaling of treatment and 
prevention in South Africa) is ‘misleading 
and dangerous’, warn local civil society 
activists and researchers.
Speaking at the launch of their review 
of the government’s National Strategic 
Plan (NSP) for HIV, sexually transmitted 
infections (STIs) and tuberculosis (TB) 
(2012 - 2016), were the Treatment Action 
Campaign (TAC) and Section 27, plus 
groundbreaking leaders in antiretroviral 
therapy (ART) Médecins Sans Frontières 
(MSF) and leading HIV clinician Prof. 
Francois Venter. They were partially backed 
by Prof. Alan Whiteside, the outgoing head 
of the self-funded Health Economics and 
HIV/AIDS Research Division (HEARD) at 
the University of KwaZulu-Natal. 
These bodies’ views provide a cold and 
often unwelcome counterpoint to the national 
department of health (NDoH’s) proud 
broadcasting of South Africa (SA’s) dramatic 
AIDS turnaround, and the premature global 
political trend of claiming imminent victory 
over the pandemic. The debate came during 
the International Conference on AIDS and 
STIs in Africa (ICASA) held in Cape Town 
in early December. 
Whiteside defined an end to AIDS as 
zero new infections or adult transmission, 
100% prevention of mother-to-child HIV 
infection and total medical and blood safety, 
concluding that this is unlikely. ‘What’s most 
likely is that it will become a low-level 
endemic disease, unless we come up with a 
vaccine or a cure. No-one living with AIDS? 
Certainly not in my lifetime. Everyone on 
treatment? Possible, but unlikely.’ 
Touting what he called the ‘economic 
transition theory’, Whiteside said health is 
simply not on the global priority list, with 
neither enough resources nor political will 
available. SA, like several countries carrying 
similar, if lesser HIV burdens, is ‘locked 
in an economic trap’ with no economic 
transition apparent. International funding 
streams are uncertain, forcing countries 
like ours to plumb insufficient domestic 
resources. Ministries of health and finance 
live in a waking nightmare in which need for 
treatment is always increasing while the rate 
of HIV infections stubbornly refuses to come 
down. Displaying graphs depicting ‘advocacy 
and epidemiological transition points’, 
Whiteside highlighted the intersection of 
the curve showing the numbers of people on 
treatment with that showing the number of 
those needing treatment, commenting, ‘We 
need to celebrate our real successes.’ The 
second transition (or ‘tipping’) point will be 
where the number of people on treatment 
exceeds the number of new infections. 
What is ‘really interesting’ is seeing how 
the more people are put on treatment, the 
lower the rates of death and new infection 
(especially with treatment as prevention)
become. ‘The intersecting lines move. Things 
happen faster and sooner than before, saving 
lives, money and time. That’s when we start 
moving to the end of AIDS.’ Whiteside 
said SA has lost four crucial years in which 
preventative measures weren’t taken and 
now simply ‘has to turn off the tap’ of AIDS 
infection, while treatment remains crucial 
‘for medical, moral, ethical and economic 
reasons’.
‘We’re in control, but 
far from winning’ – 
Heywood
Mark Heywood of the TAC said that, for the 
first time, ‘we can see that we’re controlling 
the epidemic and it’s not controlling us’. 
However, talking about the end of AIDS is 
‘misleading, potentially demobilising and 
irresponsible’. He appealed to UNAIDS to 
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‘put this talk back in the can as quickly as 
possible’. He said that while a great deal 
had changed since the 1980s, the most 
recent (2012) United Nations report showed 
2.3 million new infections and 1.6 million 
deaths worldwide, with 10 million Africans 
still waiting for treatment. Globally, HIV 
coverage of children remains half that of 
adults. While HIV is a virus, AIDS ‘has 
always been about the conditions that 
facilitate the transmission of the virus’, said 
Heywood. He identified obstacles such as 
sex work remaining criminalised, inequality 
and violence continuing unchecked, and 
stigma and discrimination, which he said are 
‘slightly lower, but still hinder us’. 
He also warned that governments, riding the 
wave of AIDS successes, are pushing back civil 
society’s hold on the reins of accountability 
at global and national level. Many structures, 
such as AIDS councils in many countries, have 
become ‘ossified, corrupt and conservative’ 
– a real problem because they are most often 
the gatekeepers of global funds. UNAIDS has 
fundamentally shifted the focus of its response 
paradigm from human rights to investment 
returns, overemphasising the biomedical 
approach while only paying lip service to a 
societal response.
Currently, non-govermental organisations 
(NGOs) are fighting for survival, thus 
lessening government accountability, while 
deeply socially entrenched and enduring 
problems facilitate the spread of AIDS. 
There is no guarantee of a steady exponential 
response to AIDS, Heywood stressed. ‘We 
didn’t campaign for a sufficient number of 
people to be on treatment, but for all people’s 
right to be on treatment. At best we are 
nowhere near the end of AIDS. There are 
dark clouds ahead. We have to determine 
the social and political determinants of 
AIDS and weaknesses in our health systems 
like drug stock-outs. Civil society is being 
corporatised and co-opted. I guess I have to 
apologise for being a spanner in the end-of-
AIDS works!’ he joked.
Learn how many are  
in care
SA’s National Health Minister Dr Aaron 
Motsoaledi acknowledges ‘logistical prob-
lems when it comes to drug distribution’, but 
notes that sometimes stock-outs are caused 
by the drug industry. Another issue is the 
thorny and largely unquantified question 
of retention in care, which HIV activists 
allege that government is deliberately 
avoiding to put the best spin on its success 
so far. Motsoaledi responds: ‘Look at our 
life expectancy figures that are increasing. I 
think they answer that question.’ 
With 2.4 million people on ART (up from 
923 000 in 2009), 3 540 HIV treatment 
sites established (up from 490 in 2009), 
and 23 000 nurses able to initiate patients 
on treatment compared with 250 four 
years ago, activists and researchers agree 
that the health department should take a 
bow. However Heywood and Venter, in their 
NSP review, say the lack of monitoring and 
evaluation could prove the Achilles’ heel of 
these major gains. They stress that the South 
African National AIDS Council (SANAC) 
still has no evaluation framework in place, so 
there’s no way of knowing how many people 
are dropping out of treatment, for whatever 
reason. 
South Africa’s national figures reflect the 
total number of people who have ever been 
initiated on treatment, but vitally fail to reveal 
the numbers of those currently in care. Says 
Heywood, ‘We cannot continue not knowing 
that for very much longer. Without this 
knowledge, what we’re accepting as truths 
could lead us into an entirely different space.’
Stock-outs burst 
treatment success bubble
Heywood said that while the TAC has 
received extensive praise for its role in battling 
denialism and forcing ART breakthroughs, 
recent experience has convinced him that 
government and SANAC believe that fight is 
now in the past, ‘and it’s all milk and honey 
– independent criticism should be muted. 
In fact, some provinces are showing a fierce 
intolerance of independence.’ 
He cited a raid on the SANAC office in 
Bloemfontein last year by Free State officials 
variously identifying themselves as either 
the Hawks or ‘security from the Health 
MEC’s office’, in which several computers 
were ‘confiscated’. Many members of the 
civil-society Stop Stock Outs coalition, who 
also serve on SANAC, operate from SANAC 
offices and had a pivotal role in exposing 
the fact that 54% of Free State facilities 
experienced drug stock-outs over the past 
three months.
The Free State’s TAC leader also received 
anonymous death threats over the phone 
and was reassigned out of the province as a 
security precaution, Heywood revealed. He 
said the raid had been reported to Deputy 
President Kgalema Motlanthe via SANAC.
In September and October last year the 
TAC and Section 27, under the umbrella  of 
the Stop Stock Outs coalition, released the 
results of a nationwide telephonic survey 
showing that one in five facilities (459 
of 2 139 or 21%) reported a stock-out or 
shortage in the preceding three months. 
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Half of these were still facing shortages 
at the time of the survey. Six out of the 
nine provinces had more than 17% of their 
facilities reporting shortages. Almost half 
of antiretroviral (ARV) stock-outs were of 
lamivudine, efavirenz or stavudine while the 
median duration of shortages was 30 days, 
ranging from one day to one year. In 20% 
of all facilities patients were sent home or 
referred elsewhere – without medicines. 
The report – worse than many feared – 
rocked the public health sector because of its 
grave implications for the health system and 
patients, including drug resistance, decreased 
immunity, increased risk of opportunistic 
infections and higher overall transmission 
rates.
NHLS the key – Venter 
and Rees
Prof. Venter, Deputy Executive Director 
at the University of the Witwatersrand’s 
Reproductive Health and HIV Institute, 
estimates that at every stage of HIV care 
(from the initial test, to receiving follow up 
CD4+ cell count results, to being placed on 
treatment) a staggering 50% of patients are 
lost. He cites studies showing that patients 
are more likely to fall out of the system 
between the time they are tested for HIV and 
the time they become eligible for treatment. 
Venter and his colleague Prof. Helen Rees 
make an impassioned plea in the NSP review 
for better use of data from the National 
Health Laboratory Service (NHLS) to 
understand how many people are falling off 
treatment, how many are virally suppressed 
and what their CD4+ cell counts are.
Venter lashed out at provinces for playing 
‘brinkmanship’ with the NHLS by not paying 
their bills, and said the level of defensiveness 
when provinces are confronted with 
disturbing facts makes it difficult to hold 
them accountable. ‘National [government] 
will admit to problems, but the minute you 
go down to the provinces, there’s a problem,’ 
he said. He said the NHLS is an invaluable 
ally in improving the performance of the 
NSP, and called it ‘inexcusable’ that it has 
been undermined by the provinces to the 
point where its services are in danger of 
being shut down.
Department responds 
Dr Yogan Pillay, Deputy Director General 
of HIV/AIDS, TB and Maternal, Child and 
Women’s Health at the NDoH scotched many 
of the activists’ claims. He told Izindaba 
that his department’s Tier.net system for 
monitoring the ARV rollout had ‘back-
captured’ data from 1 600 facilities to 2004, 
including loss-to-follow-up, viral loads, 
CD4+ counts and viral suppression. His plan 
is to roll Tier.net out to all 3 000 public 
sector ART-providing facilities, ‘in a virtual 
analogue of the TB register’. 
Using World Health Organization (WHO) 
registration guidelines, the department has 
migrated data from more than 1 600 facilities 
from Tier One (paper based) to Tier Two 
(electronic and easier to analyse). The next 
step (Tier Three) will provide an electronic 
medical record for each individual patient 
to allow clinicians to access their treatment 
history, wherever they present. ‘We’re now 
moving those facilities with a large number 
of patients to Tier Three, and within three 
years hope to embrace all our ART facilities,’ 
said Pillay. He said that Tier Two is currently 
being ‘bedded down’ at facility level. Both 
the President’s Emergency Plan For AIDS 
Relief (Pepfar) and the Global Fund are 
helping bankroll the hiring and training of 
data capturers. A full publication of ‘how we 
are doing’ is due shortly.
Regarding activists’ claims about drug stock-
outs, Pillay said the NDoH has been working 
with a wide cross-section of civil society 
organisations ‘for a significant amount of 
time trying to solve the problems. To write 
a report as if this is not the case is a little bit 
disingenuous.’
He added, ‘I’m not suggesting for 
a moment that there are no stock-outs, 
but the reports analysis and methodology 
overestimates the extent.’ Pillay said 
monitoring systems are in place (via 
district pharmacists, provinces, the AIDS 
hotline and civil society, including the HIV 
Clinicians Society). There are a number of 
reasons for stock outs, not the least of which 
is the long supply chain. ‘Nobody wants 
patients moving onto second- and third-
line drugs, least of all us,’ he added.
Asked to give examples of where the drug 
shortage survey was exaggerated, Pillay said 
‘just a few’ include reporting stock-outs of 
600 mg pills, when the same facility had 
identical 200 mg preparations (i.e. three pills 
dispensed instead of one), and alleging a 
shortage of stavudine when his staff are busy 
switching patients onto a replacement drug 
because of side-effects.
‘To call these stock-outs is just confusing. My 
big concern, which I’ve conveyed to Mark 
(Heywood), is that if you make too big a deal 
out of stock-outs, patients will read this and 
simply stop bothering to come – and we’ll end 
up with an unintended consequence, feeding 
into non-adherence.’ Pillay added, ‘We must 
work together to ensure there are no stock-outs.’
The battle is obviously far from over: 
provincial complacency, denialism and 
mistrust still drive death and sickness – 
though thankfully no longer on a holocaust-
like scale. Meanwhile, however, engagement 
between previously implacable enemies 
comes as a welcome relief.
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South Africa’s national figures 
reflect the total number of people 
who have ever been initiated 
on treatment, but vitally fail 
to reveal the numbers of those 
currently in care.
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